Welcome to our dedicated page for Cardinal Health SEC filings (Ticker: CAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cardinal Health, Inc. (NYSE: CAH) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Cardinal Health is an Ohio corporation whose common shares trade on the New York Stock Exchange under the symbol CAH, as noted in multiple Form 8-K filings. These documents give investors detailed insight into the company’s financial condition, governance, capital structure, and material events.
Cardinal Health regularly files Form 8-K current reports to announce significant developments. Recent 8-K filings include disclosures about quarterly and annual financial results, updates to fiscal 2026 non-GAAP earnings per share outlook, entry into material definitive agreements such as credit facilities and receivables purchase amendments, public offerings of notes to help fund acquisitions like Solaris Health, and the completion of those offerings. Other 8-Ks document matters such as the 2025 Annual Meeting of Shareholders and voting results on director elections, say-on-pay, and auditor ratification.
The company’s definitive proxy statement on Schedule 14A (DEF 14A) offers extensive information on corporate governance, Board composition, executive compensation, and shareholder voting items. Cardinal Health’s proxy materials describe its strategic priorities, fiscal performance highlights, Board skills and refreshment, and engagement with shareholders.
Through Stock Titan, users can review Cardinal Health’s periodic and current reports and use AI-powered tools to summarize key points from lengthy filings. These tools help explain complex sections, highlight items such as non-GAAP metrics definitions, capital markets transactions, and credit agreements, and make it easier to track themes like Specialty growth, distribution network investments, and capital allocation. The filings page also surfaces relevant exhibits, including indentures, underwriting agreements, and amendments to financing arrangements, giving a structured view of Cardinal Health’s obligations and governance framework.
The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A regarding Cardinal Health Inc. Common Stock. The filing states that, following an internal realignment effective January 12, 2026, The Vanguard Group reports 0 shares beneficially owned and 0% of the class. The amendment explains certain subsidiaries and business divisions will report beneficial ownership separately in reliance on SEC Release No. 34-39538 (January 12, 1998), and that The Vanguard Group no longer is deemed to have beneficial ownership over securities held by those subsidiaries. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Cardinal Health, Inc. reported that on March 2, 2026, Senior Vice President and Chief Accounting Officer Mary Scherer notified the company of her intention to retire in February 2027. The company plans to conduct a search for her successor.
Scherer will continue serving as Chief Accounting Officer until a new executive is identified and onboarded to support a smooth transition in the company’s accounting leadership.
Cardinal Health Chief Information Officer Michelle D. Greene reported two open-market sales of Cardinal Health common shares. On February 27, 2026, she sold 100 shares at $228.55 and 2,646 shares at $228.47, for a total of 2,746 shares sold. After these transactions, she directly owned 12,230 common shares of Cardinal Health.
Cardinal Health, Inc. submitted a Form 144 notice indicating a proposed sale of 2,746 common shares with a filing date of 02/27/2026. The disclosure lists restricted stock vesting events of 1,973 shares on 08/15/2024 and 773 shares on 03/15/2024.
Cardinal Health Chief Financial Officer Aaron E. Alt reported two recent transactions in the company’s common shares. On February 18, 2026, he completed an open-market sale of 2,328 shares at an average price of $225.50 per share. On February 15, 2026, 1,914 shares were disposed of to cover tax withholding obligations tied to the vesting of 4,242 restricted share units, using a price of $220.79 per share that reflects the prior business day’s close. After these transactions, Alt directly owns 26,408 common shares of Cardinal Health.
Cardinal Health director Patricia Hemingway Hall reported a sale of company stock. On 02/06/2026, she sold 4,000 Common Shares of Cardinal Health at a price of $229.72 per share. After this transaction, she directly holds 28,264 Cardinal Health common shares.
Cardinal Health received a notice of proposed sale under Rule 144 for its common stock. A holder who acquired shares as board compensation on 11/06/2019 and 11/04/2020 plans to sell 4,000 common shares through Merrill Lynch on the NYSE around 02/06/2026, with an aggregate market value of 918,760. Cardinal Health had 235,316,016 common shares outstanding at the time referenced in the notice.
Cardinal Health delivered strong growth for the quarter ended December 31, 2025. Revenue rose 19% to $65.6 billion, driven mainly by branded and specialty pharmaceuticals, while six-month revenue increased 21% to $129.6 billion. GAAP operating earnings grew 29% to $707 million and non-GAAP operating earnings were up 38% to $877 million.
GAAP diluted EPS increased 19% to $1.97, with non-GAAP diluted EPS up 36% to $2.63, reflecting contributions from recent acquisitions and stronger pharma and generics performance, partly offset by higher interest expense. The company completed the $1.9 billion Solaris Health acquisition, continued integrating other MSO platforms, repurchased $758 million of shares, paid $251 million in dividends, and ended the quarter with $2.8 billion in cash and $9.0 billion of long-term obligations while carrying $4.3 billion in opioid-related accruals.